(Q33378876)

English

AFFECT: a prospective, open-label, multicenter trial to evaluate the feasibility and safety of a short-term treatment with subcutaneous certoparin in patients with persistent non-valvular atrial fibrillation

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

AFFECT: a prospective, open-label, multicenter trial to evaluate the feasibility and safety of a short-term treatment with subcutaneous certoparin in patients with persistent non-valvular atrial fibrillation (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

multicenter clinical trial

0 references

atrial fibrillation

0 references

object named as

Job Harenberg

9

0 references

author name string

Ulrich Tebbe

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ralph Oeckinghaus

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Karl-Friedrich Appel

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hubertus Heuer

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hendrik Haake

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Egbert Eggers

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Karlheinz Seidel

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jan Adams

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

5 March 2008

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Clinical Research in Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

97

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

389-396

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1007%2FS00392-008-0644-Y

21 January 2018

The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg.

1 reference

https://api.crossref.org/works/10.1007%2FS00392-008-0644-Y

21 January 2018

Risk factors for intracranial hemorrhage in outpatients taking warfarin

1 reference

https://api.crossref.org/works/10.1007%2FS00392-008-0644-Y

21 January 2018

A comparison of rate control and rhythm control in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1007%2FS00392-008-0644-Y

21 January 2018

Long-term prognosis after cardioversion of the first episode of symptomatic atrial fibrillation: a condition believed to be benign revised

1 reference

https://pubmed.ncbi.nlm.nih.gov/18322636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The prognostic impact of successful cardioversion of atrial fibrillation in patients with organic heart disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18322636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18322636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anticoagulation with low-molecular-weight heparin in patients with heart diseases.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18322636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin

1 reference

https://pubmed.ncbi.nlm.nih.gov/18322636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxapar

1 reference

https://pubmed.ncbi.nlm.nih.gov/18322636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hotline update of clinical trials and registries presented at the German Cardiac Society Meeting 2007: 2L-Registry, Kardio-Pro, EVER, AFFECT, VTACH, ARTS II, OPTAMI, PEPCAD I, PEPCAD II, GERSHWIN, SPICE, FIX-CHF and CREDIT.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18322636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin

1 reference

https://pubmed.ncbi.nlm.nih.gov/18322636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pre- and post-cardioversion transesophageal echocardiography for brief anticoagulation therapy with enoxaparin in atrial fibrillation patients: a prospective study with a 1-year follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/18322636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18322636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin

1 reference

https://pubmed.ncbi.nlm.nih.gov/18322636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18322636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18322636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18322636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: Assessment of Cardioversion Using Transoesophageal Ech

1 reference

https://pubmed.ncbi.nlm.nih.gov/18322636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00392-008-0644-Y

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33378876&oldid=2195303394"